‘It has contributed 350 technologies to various sectors during the last one year’
The Defence Research and Development Organisation (DRDO) hit the headlines two months ago when the Drugs Controller General of India (DCGI) approved anti-COVID oral drug, 2-deoxy-D-glucose (2-DG), developed by it.
Having transferred many technologies to the industry sector in general and healthcare in particular during the pandemic, the DRDO has now geared up to supply small oxygen cylinders to the patients in the event of the third wave of coronavirus pandemic, apart from manufacturing 2-DG drug in a massive way.
Speaking to The Hindu, DRDO G. Satheesh Reddy says that the DRDO contributed 350 technologies to the industry during the last one year.
Of this, 190 were related to the COVID-19, while the rest were related to defence sector. Defence laboratories were opened for conducting tests, he says.
“Now, the DRDO is developing technologies to produce small oxygen cylinders in a massive way….